SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is a top trending stock following its earnings report, which, despite beating estimates, has been overshadowed by concerns regarding the Warner Bros Discovery acquisition. The community is sharply divided, with bulls viewing the current dip as an oversold opportunity for long-term content expansion, while bears cite the deal's cost, debt implications, and paused share buybacks as reasons for further downside. This strategic move and its perceived impact on future margins are driving intense discussion and significant price action.

Brand Engagement Network, Inc. engages in the provision of conversational artificial intelligence assistants with the purpose of transforming engagement and analytics for businesses through security-focused, multimodal communication and human-like artificial intelligence assistants. The firm is also involved in delivering highly personalized, multi-modal artificial intelligence engagement with a focus on industries where there is a massive workforce gap and an opportunity to transform how consumers engage with networks, providers, and brands. The company is founded on March 14, 2024 and is headquartered in Jackson, WY.

Brand Engagement Network Inc

Brand Engagement Network ($BNAI) is experiencing significant market attention following news of a strategic AI licensing partnership in Africa, including a pilot program with Nelson Mandela University. This development, combined with discussions around a reportedly thin float and high short interest, is driving substantial pre-market volatility and community speculation about a potential short squeeze. Traders are actively monitoring for sustained momentum, positioning BNAI as a key focus within the AI sector narrative.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical (DRTS) is trending with immense community excitement, primarily driven by the high anticipation of potential PMDA Japan approval for its Alpha DaRT therapy, following compelling pancreatic cancer data. Investors are increasingly bullish, viewing recent strong clinical updates and growing institutional interest as key catalysts for this innovative oncology technology, which many believe is poised for significant recognition.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending due to immediate market uncertainty surrounding an anticipated speech by Donald Trump at Davos, sparking community debate over potential tariffs and geopolitical tensions, particularly regarding Greenland. Sentiment is split, with some traders concerned about rising Japanese bond yields and broader market weakness, while others expect a rebound, highlighting underlying economic resilience and a potential rotation into small-cap and value stocks.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

SPDR Gold Shares ETF (GLD) is experiencing a parabolic rally to new record highs, driven by escalating global trade tensions and broad geopolitical uncertainty. The community is actively discussing gold's role as a safe haven amidst concerns over sovereign debt, potential currency debasement, and central bank diversification, fueling significant short-covering and strong bullish momentum.

ProShares Trust - ProShares UltraShort Bloomberg Natural Gas -2x Shares

ProShares UltraShort Bloomberg Natural Gas

KOLD is experiencing significant volatility and declines as natural gas futures surge dramatically, driven by widespread "Arctic Blast" weather forecasts across the US. This rapid price action is causing extreme pressure for many traders, leading to discussions of a "widowmaker" market as some cautiously "buy the dip" on KOLD while others are caught in the squeeze.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending as President Trump's aggressive rhetoric regarding Greenland and potential new tariffs, coupled with concerns over Japan's bond market, fuels a broad market sell-off. The community is sharply divided, with many anticipating further declines and a retest of crucial support levels, while others expect an eventual 'buy the dip' recovery, viewing current fears as an overreaction.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is trending due to overwhelmingly positive Phase 1 clinical trial results for its atopic dermatitis drug, soquelitinib, demonstrating strong efficacy and a favorable safety profile even in treatment-resistant patients. This promising early data has ignited bullish sentiment about its blockbuster potential and possible short squeeze, despite community concerns surrounding a recently announced public offering to fund future trials.

Hycroft Mining Holding Corp. engages in the exploration, mining, and development of gold and silver properties. The company was founded on August 28, 2017 and is headquartered in Winnemucca, NV.

Hycroft Mining Holding Corporation - Ordinary Shares - Class A

Hycroft Mining Holding Corp

Hycroft Mining is trending due to reports of exceptionally high-grade silver drill results across its vast land, significantly boosting optimism for future production. The community is actively discussing continuous insider buying by Eric Sprott and surging precious metal prices as catalysts for substantial upside, while also considering the company's non-producing status and potential for dilution. This confluence of factors, coupled with discussions of a possible short squeeze and growing silver demand, is driving intense conversation around the mining company.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is experiencing heightened volatility and intense discussion, largely influenced by President Trump's remarks at the Davos World Economic Forum and ongoing geopolitical tensions. The community remains deeply divided, with many bears highlighting significant drops and questioning Bitcoin's safe-haven status amidst rising gold prices, while bulls emphasize strong accumulation by institutional players and technical indicators pointing to a potential rebound from leveraged short attacks.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

U.S. stock markets spiraled lower last week as President Donald Trump's sweeping reciprocal tariffs rattled global investors.&nbsp;But while tech and industrials bore the brunt of the selloff, healthcare stocks showed surprising resilience — living up to their reputation as a defensive haven during periods of economic uncertainty.Here are three names from the sector that stood out&nbsp;with staggering weekly gains, offering retail traders on Stocktwits a rare dose of optimism in an otherwise chaotic week:iCoreConnect Inc (ICCT) - 1,579% weekly gain&nbsp;Ocoee, Florida-based iCoreConnect offers software-as-a-service for the healthcare market. Last week, there were no major news catalysts for the stock, although it has seen heavy trading volume since the beginning of April.&nbsp;On Stocktwits, sentiment remained 'extremely bullish' last week amid stunning gains, with followers jumping by 69% and message volume exploding by over 40,400%.&nbsp; &nbsp;<figure class="image"><img style="aspect-ratio:1318/316;" src="https://news.stocktwits-cdn.com/ICCT_sentiment_and_message_volume_as_of_April_6_png_16855887e8.webp" alt="ICCT sentiment and message volume as of April 6.png" width="1318" height="316"><figcaption>ICCT sentiment and message volume as of April 6. | source: Stocktwits</figcaption></figure>Recent posts suggest that retail traders anticipate a major development, though many dismissed the possibility of another equity offering —something the company has done multiple times.Last year, the company received the backing of several state dental associations for its cloud solutions and made some strategic acquisitions.BioAffinity Technologies Inc (BIAF) - 163% weekly gain&nbsp;San Antonio, Texas-based BioAffinity is a company focused on making products for the early detection of cancers. Its initial product, CyPath Lung, uses a patient's sputum and proprietary automated flow cytometry data analysis to diagnose early-stage lung cancer accurately.Last week, Maxim — the sole research firm covering the stock — downgraded BioAffinity to 'Hold' from 'Buy' after the company posted annual financial results.BioAffinity's 2024 revenue increased 270% from a year earlier, primarily due to the acquisition of Precision Pathology Laboratory Services (PPLS). However, the company's net loss also increased due to higher operating expenses.In March, BioAffinity said it expects to realize most of its planned $4 million in annual cost savings through workforce and operational cuts at PPLS and improving operational efficiency by cutting supply and service costs.&nbsp;<figure class="image"><img style="aspect-ratio:1318/316;" src="https://news.stocktwits-cdn.com/BIAF_sentiment_and_message_volume_as_of_April_6_png_0a9f433739.webp" alt="BIAF sentiment and message volume as of April 6.png" width="1318" height="316"><figcaption>BIAF sentiment and message volume as of April 6. | source: Stocktwits</figcaption></figure>On Stocktwits, sentiment ended Friday higher in the 'extremely bullish' zone amid a 3,750% spike in weekly message volume.Alaunos Therapeutics Inc (TCRT) - 102% weekly gain&nbsp;Houston, Texas-based Alaunos is a biotech firm that also rocketed last week with virtually no major news catalysts, with Stocktwits sentiment flipping to 'extremely bullish' from 'neutral.'&nbsp;Regulatory filings from April 1 revealed that senior executives, including interim CEO Dale Curtis Hogue, exercised options to buy 7,000 shares at $1.46 apiece.&nbsp;The company's annual 10-K report also showed that Alaunos' 2024 revenue doubled to $10,000, while net loss shrank to $4.6 million from $35.1 million a year earlier.&nbsp;Alaunos significantly cut expenses by winding down clinical programs, such as its costly TCR-T clinical trial, and reducing headcount.&nbsp;The company is exploring strategic options such as mergers, partnerships, or asset sales.&nbsp;<figure class="image"><img style="aspect-ratio:1318/316;" src="https://news.stocktwits-cdn.com/TCRT_sentiment_and_message_volume_as_of_April_6_png_163e68145a.webp" alt="TCRT sentiment and message volume as of April 6.png" width="1318" height="316"><figcaption>TCRT sentiment and message volume as of April 6. | source: Stocktwits</figcaption></figure>Alaunos is now focused on its small molecule oral obesity drug program, which aims to offer a differentiated alternative to injectable GLP-1 therapies by preserving lean muscle mass.&nbsp;Alaunos regained Nasdaq compliance in February and expects its current cash reserves to last into the second quarter.For updates and corrections, email newsroom[at]stocktwits[dot]com.

These 3 Healthcare Stocks Show Serious Muscle Amid Trump Tariff Turmoil: Are Retail Traders Feeling Bullish?

iCoreConnect, BioAffinity and Alaunos Therapeutics posted strong gains last week amid heavy trading volume.

Equity

iCoreConnect, BioAffinity and Alaunos Therapeutics posted strong gains last week amid heavy trading volume.


Alaunos Therapeutics, Inc. is a biopharmaceutical company and clinical-stage oncology-focused cell therapy company, which engages in the development of adoptive TCR engineered T-cell therapies, or TCR-T, designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs. Its pipeline includes Library TCR-T cell and mblL-15 TCR-T cell Therapy. The company was founded in 2003 and is headquartered in Fort Lauderdale, FL.

Alaunos Therapeutics Inc

Up 10% or more

0% to up 9%

Down 1% to 9%

Down 10% or more

The S&P 500 enters 2026 after a strong run. What kind of return do you expect this year?

How will the S&amp;P 500 perform in 2026?

TCRT
Alaunos Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest TCRT News

TCRTAlaunos Therapeutics Inc